Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy
Primary Purpose
Nonarteritic Anterior Ischemic Optic Neuropathy
Status
Completed
Phase
Phase 4
Locations
Iran, Islamic Republic of
Study Type
Interventional
Intervention
levodopa-carbidopa
Sponsored by
About this trial
This is an interventional treatment trial for Nonarteritic Anterior Ischemic Optic Neuropathy
Eligibility Criteria
Inclusion Criteria:
- age greater than 50 years old
- first ophthalmic examination within 6 weeks after onset of disease
- presence of optic disc swelling followed by optic atrophy within 6 weeks
- altitudinal, central or generalized visual field defect
- normal ESR
Exclusion Criteria:
- confirmed giant cell arteritis
- history of any ocular surgeries
- optic neuropathy due to acute bleeding
- advanced diabetic retinopathy
- uncontrolled glaucoma
- any ocular disorders that cause visual acuity reduction rather than NAION
Sites / Locations
- Ophthalmic research center
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00432393
First Posted
February 6, 2007
Last Updated
October 17, 2008
Sponsor
Shahid Beheshti University of Medical Sciences
1. Study Identification
Unique Protocol Identification Number
NCT00432393
Brief Title
Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy
Official Title
Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy
Study Type
Interventional
2. Study Status
Record Verification Date
February 2007
Overall Recruitment Status
Completed
Study Start Date
June 2002 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
April 2003 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Shahid Beheshti University of Medical Sciences
4. Oversight
5. Study Description
Brief Summary
Purpose: There are some controversies about the effect of Levodopa-Carbidopa on treatment of non-arteritic anterior ischemic optic neuropathy (NAION). This study was performed to evaluate the effect of Levodopa-Carbidopa on visual acuity, color vision, and visual field in patients with recent onset NAION (less than 6 weeks duration).
Patients and Methods: In this double-blind randomized clinical trial, 13 patients were treated with levodopa-carbidopa and 12 patients took placebo for 3 weeks. Visual acuity, color vision, and visual field were tested before and at 4th, 12th, 16th, and 24th weeks after enrollment, and evaluated.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nonarteritic Anterior Ischemic Optic Neuropathy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
levodopa-carbidopa
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Eligibility Criteria
Inclusion Criteria:
age greater than 50 years old
first ophthalmic examination within 6 weeks after onset of disease
presence of optic disc swelling followed by optic atrophy within 6 weeks
altitudinal, central or generalized visual field defect
normal ESR
Exclusion Criteria:
confirmed giant cell arteritis
history of any ocular surgeries
optic neuropathy due to acute bleeding
advanced diabetic retinopathy
uncontrolled glaucoma
any ocular disorders that cause visual acuity reduction rather than NAION
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mohammad Pakravan, MD
Organizational Affiliation
Shahid Beheshti University of Medical Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ophthalmic research center
City
Tehran
ZIP/Postal Code
1666694516
Country
Iran, Islamic Republic of
12. IPD Sharing Statement
Learn more about this trial
Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy
We'll reach out to this number within 24 hrs